GlassScriptPhysician profile
Beth A Belesky
NPI 1245377563
$8,287.21
in general payments reported to CMS, 2019-2025
31 companies · $1,700 in 2025
The $1,700 reported for 2025 was more than what 89% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,135 · 2022: $1,649 · 2023: $1,644 · 2024: $2,160 · 2025: $1,700.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,310 · Education: $193.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,310.12 |
| Education | $193.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,329.09 | 2021-2025 | |
| Janssen Biotech, INC. | $921.02 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Sun Pharmaceutical Industries INC. | $814.82 | 2021-2025 | Ilumya, Winlevi, Absorica Ld |
| Galderma Laboratories, L.P. | $673.31 | 2021-2025 | Nemluvio, Aklief, Oracea |
| Genzyme Corporation | $633.97 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $619.13 | 2023-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $381.71 | 2021-2025 | Dupixent, Libtayo |
| Lilly USA, LLC | $337.04 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| Leo Pharma INC. | $284.47 | 2021-2025 | Anzupgo, Adbry |
| Journey Medical Corporation | $282.29 | 2021-2025 | |
| Amgen INC. | $266.45 | 2023-2025 | Otezla, Otezla |
| Dermavant Sciences, INC. | $229.44 | 2022-2024 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $214.40 | 2021-2024 | Jublia, Duobrii, Cabtreo |
| Pfizer INC. | $200.58 | 2022-2025 | |
| Vyne Pharmaceuticals INC. | $188.27 | 2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $140.39 | 2022-2025 | Opzelura |
| Almirall LLC | $120.25 | 2021-2025 | Seysara, Klisyri |
| Novartis Pharmaceuticals Corporation | $117.20 | 2022-2025 | |
| Mayne Pharma Commercial LLC | $86.10 | 2023-2025 | |
| Helsinn Therapeutics (U.S.), INC. | $77.78 | 2022 | |
| Lnhc, INC | $65.86 | 2025 | Zelsuvmi |
| Arcutis Biotherapeutics, INC. | $63.83 | 2023-2024 | Zoryve |
| Ucb, INC. | $52.80 | 2024-2025 | Bimzelx |
| Strata Skin Sciences, INC. | $41.79 | 2024-2025 | Xtrac |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.78 | 2025 | Spevigo |
| Organon LLC | $23.57 | 2025 | Vtama |
| Botanix Sb INC | $20.00 | 2025 | Sofdra |
| Biofrontera INC. | $19.65 | 2021 | |
| Verrica Pharmaceuticals INC. | $18.64 | 2024 | Ycanth |
| Epi Health, LLC | $17.74 | 2022 | |
| Cipher Pharmaceuticals US LLC | $13.84 | 2025 | Spinosad, Natroba |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beth Belesky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.